LncRNA MIR503HG Inhibits Cell Proliferation and Promotes Apoptosis in TNBC Cells Via the MiR-224-5p/HOXA9 Axis

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2021 Apr 19

PMID 33869743

Citations 11

Authors

Shou-Man Wang

Jian Pang

Ke-Jing Zhang

Zhi-Yang Zhou

Fei-Yu Chen

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a highly invasive subtype of breast cancer. This study investigated the molecular mechanism and influences of MIR503HG, miR-224-5p, and homeobox A9 (HOXA9) on TNBC cell growth and migration. Dual-luciferase reporter gene and RNA immunoprecipitation were performed to examine the regulation of MIR503HG, miR-224-5p, and HOXA9. Cell proliferation, apoptosis, migration, and invasion were evaluated by colony formation, flow cytometry, and Transwell assays. Finally, nude mice were employed to investigate the influence of MIR503HG on TNBC tumor growth. HOXA9 protein levels were detected by immunohistochemical staining. MIR503HG and HOXA9 expression were reduced in TNBC, while miR-224-5p was increased. Overexpression of MIR503HG or HOXA9 reduced the cell migration ability and proliferation and promoted apoptosis, and knockdown of MIR503HG or overexpression of miR-224-5p exhibited the opposite effects. Furthermore, MIR503HG promoted HOXA9 expression by inhibiting miR-224-5p. Overexpression of miR-224-5p reversed the effects of MIR503HG overexpression on TNBC cells, while overexpression of HOXA9 reversed the effect of MIR503HG knockdown. Additionally, an study proved that MIR503HG inhibited TNBC tumor growth via the miR-224-5p/HOXA9 axis. MIR503HG inhibited cell proliferation and promoted the apoptosis of TNBC cells via the miR-224-5p/HOXA9 axis, which may function as a novel target for the treatment of TNBC.

Citing Articles

Co-host ncRNA MIR503HG/miR-503-5p antagonistically interfere with the crosstalk between fibroblasts and microvascular endothelial cells by affecting the production of LMW FGF2 in pterygium.

Yuan Y, Yan X, Zheng F, Yan M Int J Ophthalmol. 2025; 18(2):199-208.

PMID: 39967972 PMC: 11754036. DOI: 10.18240/ijo.2025.02.01.

Protective Effects of Baicalein on Lipopolysaccharide-Induced AR42J PACs through Attenuation of Both Inflammation and Pyroptosis via Downregulation of miR-224-5p/PARP1.

Liu M, Zhang C, Ma S, Zhang D, Jiang L, Tan Y Mediators Inflamm. 2024; 2024:6618927.

PMID: 39421730 PMC: 11486537. DOI: 10.1155/2024/6618927.

HOXA9 transcription factor is a double-edged sword: from development to cancer progression.

Shenoy U, Adiga D, Alhedyan F, Kabekkodu S, Radhakrishnan R Cancer Metastasis Rev. 2023; 43(2):709-728.

PMID: 38062297 PMC: 11156722. DOI: 10.1007/s10555-023-10159-2.

WFDC21P promotes triple-negative breast cancer proliferation and migration through WFDC21P/miR-628/SMAD3 axis.

Wei Y, Liang D, Zhang M, Li Y, Sun H, Wang Q Front Oncol. 2022; 12:1032850.

PMID: 36387210 PMC: 9659817. DOI: 10.3389/fonc.2022.1032850.

Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential.

Tang L, Peng L, Tan C, Liu H, Chen P, Wang H Cancer Cell Int. 2022; 22(1):349.

PMID: 36376832 PMC: 9664671. DOI: 10.1186/s12935-022-02767-9.

References

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W . MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014; 9(5):e96228. PMC: 4008525. DOI: 10.1371/journal.pone.0096228. View

Reddy K . MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015; 15:38. PMC: 4424445. DOI: 10.1186/s12935-015-0185-1. View

Sun M, Song C, Huang H, Frankenberger C, Sankarasharma D, Gomes S . HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A. 2013; 110(24):9920-5. PMC: 3683728. DOI: 10.1073/pnas.1305172110. View

Dao R, Wudu M, Hui L, Jiang J, Xu Y, Ren H . Knockdown of lncRNA MIR503HG suppresses proliferation and promotes apoptosis of non-small cell lung cancer cells by regulating miR-489-3p and miR-625-5p. Pathol Res Pract. 2020; 216(3):152823. DOI: 10.1016/j.prp.2020.152823. View

Malek R, Gajula R, Williams R, Nghiem B, Simons B, Nugent K . TWIST1-WDR5- Regulates Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Res. 2017; 77(12):3181-3193. PMC: 5489316. DOI: 10.1158/0008-5472.CAN-16-2797. View

Mavridis K, Stravodimos K, Scorilas A . Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem. 2012; 59(1):261-9. DOI: 10.1373/clinchem.2012.191502. View

Chuo D, Liu F, Chen Y, Yin M . LncRNA MIR503HG is downregulated in Han Chinese with colorectal cancer and inhibits cell migration and invasion mediated by TGF-β2. Gene. 2019; 713:143960. DOI: 10.1016/j.gene.2019.143960. View

Cui R, Meng W, Sun H, Kim T, Ye Z, Fassan M . MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci U S A. 2015; 112(31):E4288-97. PMC: 4534291. DOI: 10.1073/pnas.1502068112. View

Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B . Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol. 2012; 15(7):569-74. DOI: 10.1007/s12094-012-0972-2. View

10.

Fu J, Dong G, Shi H, Zhang J, Ning Z, Bao X . LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. J Cell Mol Med. 2019; 23(7):4738-4745. PMC: 6584514. DOI: 10.1111/jcmm.14344. View

11.

Yang F, Zhang W, Shen Y, Guan X . Identification of dysregulated microRNAs in triple-negative breast cancer (review). Int J Oncol. 2015; 46(3):927-32. DOI: 10.3892/ijo.2015.2821. View

12.

da Silva J, Nunes N, Izetti P, Gomes de Mesquita G, de Melo A . Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 2020; 145:102855. DOI: 10.1016/j.critrevonc.2019.102855. View

13.

Turashvili G, Lightbody E, Tyryshkin K, SenGupta S, Elliott B, Madarnas Y . Novel prognostic and predictive microRNA targets for triple-negative breast cancer. FASEB J. 2018; :fj201800120R. DOI: 10.1096/fj.201800120R. View

14.

Gilbert P, Mouw J, Unger M, Lakins J, Gbegnon M, Clemmer V . HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest. 2010; 120(5):1535-50. PMC: 2860938. DOI: 10.1172/JCI39534. View

15.

Mulrane L, McGee S, Gallagher W, OConnor D . miRNA dysregulation in breast cancer. Cancer Res. 2013; 73(22):6554-62. DOI: 10.1158/0008-5472.CAN-13-1841. View

16.

Lv M, Xu P, Wu Y, Huang L, Li W, Lv S . LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer. Oncotarget. 2016; 7(11):13047-59. PMC: 4914340. DOI: 10.18632/oncotarget.7509. View

17.

De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S . Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev. 2010; 36 Suppl 3:S80-6. DOI: 10.1016/S0305-7372(10)70025-6. View

18.

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

19.

Lin A, Li C, Xing Z, Hu Q, Liang K, Han L . The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol. 2016; 18(2):213-24. PMC: 4791069. DOI: 10.1038/ncb3295. View

20.

Tang J, Li Y, Sang Y, Yu B, Lv D, Zhang W . LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene. 2018; 37(34):4723-4734. DOI: 10.1038/s41388-018-0310-4. View